FDA Clearance Tracker · K250273
BinaxNOW COVID-19 Ag Card
Last checked: Nov 20, 2026Latest source record: Jun 13, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jun 13, 2025
Substantially Equivalent
Time to decision
134 days
Received Jan 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K250273
- Device name
- BinaxNOW COVID-19 Ag Card
- Applicant
- Abbott Diagnostics Scarborough, Inc.
- Applicant location
- Scarborough, ME
- Received
- Jan 30, 2025
- Decided
- Jun 13, 2025
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3982
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QVF. The earliest in FDA's data is DEN220039, decided Mar 8, 2023.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K250273
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Diagnostics Scarborough, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262747 · Decided Aug 31, 2026 · 28 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
K243518 · Decided Feb 11, 2025 · 90 days after receipt
Device type: Over-The-Counter Covid-19 Antigen Test (QYT) · Laboratory Medicine & Pathology
- ID NOW Influenza A & B 2510(k)
K232775 · Decided Oct 10, 2023 · 29 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.